Basilea Pharmaceutica AG BSLN.SW Stock
Basilea Pharmaceutica AG Price Chart
Basilea Pharmaceutica AG BSLN.SW Financial and Trading Overview
| Basilea Pharmaceutica AG stock price | 40.45 CHF |
| Previous Close | 46 CHF |
| Open | 46.05 CHF |
| Bid | 45.8 CHF x 0 |
| Ask | 46 CHF x 0 |
| Day's Range | 45.9 - 46.5 CHF |
| 52 Week Range | 30.6 - 55.4 CHF |
| Volume | 5.54K CHF |
| Avg. Volume | 30.05K CHF |
| Market Cap | 548.8M CHF |
| Beta (5Y Monthly) | 0.792337 |
| PE Ratio (TTM) | 45.445545 |
| EPS (TTM) | 0.86 CHF |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | April 11, 2013 |
| 1y Target Est | 69.62 CHF |
BSLN.SW Valuation Measures
| Enterprise Value | 652.24M CHF |
| Trailing P/E | 45.445545 |
| Forward P/E | 8.9126215 |
| PEG Ratio (5 yr expected) | 0.15 |
| Price/Sales (ttm) | 3.7139974 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.414 |
| Enterprise Value/EBITDA | 30.043 |
Trading Information
Basilea Pharmaceutica AG Stock Price History
| Beta (5Y Monthly) | 0.792337 |
| 52-Week Change | 39.60% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 55.4 CHF |
| 52 Week Low | 30.6 CHF |
| 50-Day Moving Average | 45.91 CHF |
| 200-Day Moving Average | 46.65 CHF |
BSLN.SW Share Statistics
| Avg. Volume (3 month) | 30.05K CHF |
| Avg. Daily Volume (10-Days) | 31.57K CHF |
| Shares Outstanding | 11.96M |
| Float | 11.58M |
| Short Ratio | N/A |
| % Held by Insiders | 4.16% |
| % Held by Institutions | 31.64% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 8.22% |
| Operating Margin (ttm) | 14.08% |
| Gross Margin | 33.40% |
| EBITDA Margin | 14.69% |
Management Effectiveness
| Return on Assets (ttm) | 5.55% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 147.76M CHF |
| Revenue Per Share (ttm) | 12.46 CHF |
| Quarterly Revenue Growth (yoy) | -5.099% |
| Gross Profit (ttm) | 49.36M CHF |
| EBITDA | 21.71M CHF |
| Net Income Avi to Common (ttm) | 12.15M CHF |
| Diluted EPS (ttm) | 1.01 |
| Quarterly Earnings Growth (yoy) | 86.50% |
Balance Sheet
| Total Cash (mrq) | 84.66M CHF |
| Total Cash Per Share (mrq) | 7.08 CHF |
| Total Debt (mrq) | 187.14M CHF |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.343 |
| Book Value Per Share (mrq) | -1.733 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 7.06M CHF |
| Levered Free Cash Flow (ttm) | -2005875 CHF |
Profile of Basilea Pharmaceutica AG
| Country | Switzerland |
| State | N/A |
| City | Allschwil |
| Address | Hegenheimermattweg 167b |
| ZIP | 4123 |
| Phone | 41 61 606 11 11 |
| Website | https://www.basilea.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 141 |
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Q&A For Basilea Pharmaceutica AG Stock
What is a current BSLN.SW stock price?
Basilea Pharmaceutica AG BSLN.SW stock price today per share is 40.45 CHF.
How to purchase Basilea Pharmaceutica AG stock?
You can buy BSLN.SW shares on the Swiss exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Basilea Pharmaceutica AG?
The stock symbol or ticker of Basilea Pharmaceutica AG is BSLN.SW.
Which industry does the Basilea Pharmaceutica AG company belong to?
The Basilea Pharmaceutica AG industry is Biotechnology.
How many shares does Basilea Pharmaceutica AG have in circulation?
The max supply of Basilea Pharmaceutica AG shares is 12M.
What is Basilea Pharmaceutica AG Price to Earnings Ratio (PE Ratio)?
Basilea Pharmaceutica AG PE Ratio is 47.03488500 now.
What was Basilea Pharmaceutica AG earnings per share over the trailing 12 months (TTM)?
Basilea Pharmaceutica AG EPS is 0.86 CHF over the trailing 12 months.
Which sector does the Basilea Pharmaceutica AG company belong to?
The Basilea Pharmaceutica AG sector is Healthcare.
Basilea Pharmaceutica AG BSLN.SW included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| SPI TR SSHI | 15051.28 CHF 17125.13 USD |
-0.5
|
— — | 15030.9 CHF 17101.95 USD | 15256.93 CHF 17359.12 USD | — - | — — |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}